How Have the Numbers Shaped Up for AIM ImmunoTech (NYSE:AIM)

0
184

Earnings results for AIM ImmunoTech (NYSE:AIM)

Hemispherx BioPharma, Inc. is estimated to report earnings on 09/24/2020. The upcoming earnings date is derived from an algorithm based on a company’s historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. The reported EPS for the same quarter last year was $-1.07.

Analyst Opinion on AIM ImmunoTech (NYSE:AIM)

2 Wall Street analysts have issued ratings and price targets for AIM ImmunoTech in the last 12 months. Their average twelve-month price target is $5.25, predicting that the stock has a possible upside of 131.28%. The high price target for AIM is $5.50 and the low price target for AIM is $5.00. There are currently 2 buy ratings for the stock, resulting in a consensus rating of “Buy.”

AIM ImmunoTech has received a consensus rating of Buy. The company’s average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings. According to analysts’ consensus price target of $5.25, AIM ImmunoTech has a forecasted upside of 131.3% from its current price of $2.27. AIM ImmunoTech has only been the subject of 2 research reports in the past 90 days.

Dividend Strength: AIM ImmunoTech (NYSE:AIM)

AIM ImmunoTech does not currently pay a dividend. AIM ImmunoTech does not have a long track record of dividend growth.

Insiders buying/selling: AIM ImmunoTech (NYSE:AIM)

In the past three months, AIM ImmunoTech insiders have bought more of their company’s stock than they have sold. Specifically, they have bought $50,002.00 in company stock and sold $0.00 in company stock. Only 1.40% of the stock of AIM ImmunoTech is held by insiders. Only 4.72% of the stock of AIM ImmunoTech is held by institutions.

Earnings and Valuation of AIM ImmunoTech (NYSE:AIM

AIM ImmunoTech has a P/B Ratio of 1.54. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

More latest stories: here